ArticleClinical research in cardiology : official journal of the German Cardiac Society2024
Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Critical appraisal of "Thiamin deficiency in children with chronic kidney disease on peritoneal dialysis and its association with dialysis duration and transport peritoneal membrane status".Pediatric nephrology (Berlin, Germany) · 2026Article
- Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Review
- Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies.JACC. Advances · 2026Article
- PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies.Scientific reports · 2026Article
- LDL-C lowering in patients treated with bempedoic acid in a real-world cohort.Atherosclerosis plus · 2026Article
- Less intensive lipid-lowering therapy after ST-elevation myocardial infarction is associated with cardiovascular events: 2-year follow-up of "Jena auf Ziel".Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Treatment pathways of lipid-lowering therapies in Germany 2016-2022.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Prescription of lipid-lowering drugs and their association with hospitalization for ST-elevation myocardial infarction (STEMI) in Germany in 2010-2022.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Biochemical urine analysis of atorvastatin and rosuvastatin by LC-MS: a pilot study of an objective method to assess non-adherence.BMC cardiovascular disorders · 2026Article
- Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease.Journal of the Saudi Heart Association · 2026Article
- Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Summary of the best evidence for non-pharmacological interventions for dyslipidemia in patients with coronary heart disease.Frontiers in cardiovascular medicine · 2026Review
- Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up.Cardiology and therapy · 2025Article
- Medication persistence trajectories among individuals prescribed lipid-lowering therapy in primary care settings: A retrospective cohort study.British journal of clinical pharmacology · 2025Article
- Short- and Long-Term Statin Persistence and Determinants in Patients Initiating Statin Therapy.Medeniyet medical journal · 2025Article
- Clinical and serological characterization of acute pleuropericarditis suggests an autoinflammatory pathogenesis and highlights risk factors for recurrent attacks.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Newly Started Versus Previously Treated Statin Patients: A Retrospective Cohort Study Comparing Adherence and Persistence with Reference to Cardiovascular Prevention.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Associations of patient knowledge with drug-modifiable cardiovascular risk factor control in coronary artery disease patients with and without diabetes mellitus: results from the cross-sectional KNOW-ABC study.BMC cardiovascular disorders · 2025Article
- Suboptimal management of hypercholesterolemia in countries with high or very high cardiovascular risk: findings from the international DISCOVERY study.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease is the leading cause of mortality in Germany. Cardiovascular risk can be mitigated with long-term lipid-lowering therapies (LLTs) that reduce levels of low-density lipoprotein cholesterol. Although effective, risk mitigation is hindered by poor persistence and adherence.
objectiveTo investigate real-world persistence and adherence to LLTs through 36 months post-initiation.
methodsThis retrospective cohort study included patients with dyslipidemia who were newly prescribed LLTs between July and December 2017, using anonymized prescription data from the Insight Health™ Patient Insight Tool, and followed up until March 2021. Persistence and adherence to the therapies were stratified by age and sex. The proportion of days covered (PDC) was used to measure adherence.
resultsPatients with dyslipidemia and newly prescribed statins (n = 865,732), ezetimibe (n = 34,490), or anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (anti-PCSK9 mAbs; n = 1940) were included. Persistence to LLTs declined gradually across all treatment subgroups and was lower in women than men. Adherence, calculated as the mean PDC at the end of the analysis period (July 2017‒March 2021) was 0.84, 0.92, and 0.93 for statins, ezetimibe, and anti-PCSK9 mAbs, respectively. Among patients who discontinued treatment, mean treatment duration was 265, 255, and 387 days for statins, ezetimibe, and anti-PCSK9 mAbs, respectively. Only ~ 10% of patients persisted between 201 and 300 days. By Day 300, 71% of patients on statins had discontinued treatment. At 36 months, overall persistence rates were lowest with statins (20.6%), followed by ezetimibe (22.3%) and anti-PCSK9 mAbs (50.9%).
conclusionsHigh non-persistence rates were observed across all LLT regimens analyzed, with the lowest persistence rates observed with statins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.